Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting Execution of strategic...
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs at ASGCT 2024
Cellectis publishes an approach that could unlock new therapeutic avenues for the treatment of inborn metabolic diseases as well as neurological diseases
Cellectis announces that preliminary data exploring novel TALEN® editing process in HSPCs will be presented at ASGCT 2024
PARIS, April 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Monthly information on share capital and company voting rights
Monthly information on share capital and company voting rights
Cellectis announces the drawdown of the second tranche of ‚¬15 million
PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...